ZURICH: Swiss drugmaker Novartis said on Tuesday it would exchange certain assets with GlaxoSmithKline and divest its animal health business to Eli Lilly.
Novartis said it had agreed to acquire GSK's oncology products for a $14.5 billion payment.
The Swiss drugmaker said it would divest its vaccines business, excluding flu, to GSK for $7.1 million plus royalties.
In a separate transaction, Novartis said it had agreed to divest its animal health division to Eli Lilly for approximately $5.4 billion.
Comments
Comments are closed.